Regulatory Q&A Forum
Ask questions, share knowledge, and get help from the regulatory community
For a non-EU manufacturer preparing for chemicals compliance within the European Union, selecting the right Only Representative (OR) is a foundational strategic decision. Beyond confirming that a pote...
For foreign medical device establishments planning to enter the U.S. market, appointing a U.S. Agent is a mandatory regulatory requirement. However, the exact scope and limitations of this role are of...
Given the anticipated revisions to the EU WEEE (Waste Electrical and Electronic Equipment) Directive and evolving national Extended Producer Responsibility (EPR) laws leading up to 2026, how should a ...
When planning a biocompatibility evaluation for a medical device with prolonged patient contact, such as a novel polymer-coated catheter, how should sponsors strategically navigate the potential diver...
With significant updates to the UK's medical device regulations on the horizon, how should manufacturers outside the UK proactively reassess their UK Responsible Person (UKRP) strategy to ensure compl...
For a non-EU medical device manufacturer preparing for significant EU VAT reforms scheduled for 2026, what is a comprehensive framework for selecting a VAT fiscal representative, moving beyond basic c...
For a manufacturer of a moderate-risk (Class II) medical device, what are FDA's "Special Controls," and how do they build upon the "General Controls" that apply to all devices? While General Controls ...
With significant updates to key international biocompatibility consensus standards anticipated to be recognized by regulatory bodies around 2026, how should medical device manufacturers strategically ...
With the UK's transitional arrangements for medical devices concluding, what comprehensive framework should a non-UK manufacturer use to evaluate and select a UK Responsible Person (UKRP) before the u...
With significant updates to EU cosmetic regulations anticipated, the role of the EU Responsible Person (RP) is more critical than ever for non-EU brands. The RP is not just a legal requirement but a k...
Given the evolving landscape of EU environmental compliance, particularly with potential revisions to the WEEE Directive anticipated around 2026, how should medical device manufacturers strategically ...
With ongoing discussions in the industry regarding potential updates to biocompatibility standards, including anticipated revisions to the ISO 10993 series around 2025-2026, how should medical device ...
What are the key functions of a UK Responsible Person (UKRP), and what should non-UK medical device manufacturers consider as the UK regulatory landscape evolves? A UKRP is a legal requirement for ma...
As non-EU cosmetic brands prepare for 2026 compliance deadlines, many seek to understand the associated costs of appointing an EU Responsible Person (RP). Rather than a single fixed price, the fees fo...
For a connected medical device, such as a Software as a Medical Device (SaMD) or a networked cardiac monitor, how should a sponsor prepare cybersecurity documentation for a premarket submission that n...
Given the evolving landscape of global biocompatibility standards, how should medical device sponsors strategically develop a Biological Evaluation Plan (BEP) that not only meets current FDA-recognize...
For medical device manufacturers based outside Great Britain, navigating the role of the UK Responsible Person (UKRP) is critical for market access, especially with evolving regulatory frameworks. Bey...
As the European Union’s cosmetic regulatory landscape continues to evolve, with significant substance restrictions and updated requirements anticipated through 2026, the role of a proficient Responsib...
For a non-EU based manufacturer of a connected medical device, such as a Software as a Medical Device (SaMD) that processes sensitive health data, what are the key regulatory-adjacent considerations w...
While non-EU medical device manufacturers are required to appoint an EU Authorized Representative (AR) to place products on the European market, determining the associated cost is not straightforward ...